Amvuttra (vutrisiran) is a prescription medication used to treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults [1]. It is administered via subcutaneous injection [1].
How is Amvuttra administered?
Amvuttra is given as a self-injection under the skin [1]. Patients are taught how to administer the injection themselves [1]. The recommended dose is 114 mg every three months after an initial loading dose [1].
What is the target patient population for Amvuttra?
Amvuttra is indicated for adults diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR-PN) [1]. This condition involves nerve damage causing symptoms like pain, numbness, and weakness, particularly in the hands and feet [1].
Are there alternative treatments for hATTR-PN?
Yes, other treatments are available for hATTR-PN. Patisiran (Onpattro) is another RNA interference (RNAi) therapeutic used for the same indication [2]. Tafamidis (Vyndaqel, Vyndamax) is an oral medication that works by stabilizing the transthyretin protein [3].
How do Amvuttra and patisiran compare?
Both Amvuttra and patisiran are RNAi therapies used to treat hATTR-PN. Amvuttra is administered subcutaneously every three months after a loading dose, while patisiran is given intravenously every three weeks [1, 2]. Clinical studies have shown both medications can improve neuropathy and quality of life in patients with hATTR-PN [1, 2].
When does Amvuttra's patent exclusivity expire?
Information on the specific patent expiry dates for Amvuttra is not publicly available through the provided context. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceutical products [4].
What are the potential side effects of Amvuttra?
Common side effects of Amvuttra include injection site reactions, pain in the limbs, and anemia [1]. More serious side effects can include hypersensitivity reactions and ocular issues [1].
What are the regulatory approvals for Amvuttra?
Amvuttra received approval from the U.S. Food and Drug Administration (FDA) [1].
Where can I find more information on Amvuttra and its patents?
For detailed information on Amvuttra's clinical data, prescribing information, and patent status, resources such as the drug manufacturer's website and DrugPatentWatch.com can be consulted [1, 4].
Sources:
1. https://www.amvuttra.com/
2. https://www.onpattro.com/
3. https://www.pfizer.com/products/vyndaqel
4. https://drugpatentwatch.com/